贝达药业：目前MCLA-129的临床试验工作正在有序推进中

Group 1 - The core concern raised by investors is about the potential delay in the listing of MCLA-129, suggesting that if it is not submitted soon, the competitive landscape may diminish significantly [2] - Beida Pharmaceutical (300558.SZ) has responded that the clinical trial work for MCLA-129 is progressing in an orderly manner and that the company will announce any significant developments in a timely manner [2]